文献速递血栓与止血

血友病B患者接受etranacogene dezaparvovec基因治疗后侵入性操作与手术的管理

Invasive procedures and surgery following etranacogene dezaparvovec gene therapy in people with hemophilia B.
PubMed 文献 · J Thromb Haemost · 2024-09-26

本回顾性分析纳入2b期和HOPE-B试验中接受单次2×10¹³ gc/kg etranacogene dezaparvovec输注的29例重型或中重型血友病B患者,共64例次侵入性操作。98%操作前内源性FIX活性达轻型血友病或正常水平(中位43.8 IU/dL,范围3.1-113 IU/dL),所有大手术均使用外源性FIX,67%输注≤4天,多数小手术、内镜和牙科操作无需或仅需单次FIX输注,术后出血见于1例小手术和4例牙科操作,无血栓事件或FIX抑制物发生。

要点

  • 98%操作前内源性FIX活性达轻型血友病或正常水平,中位43.8 IU/dL(范围3.1-113 IU/dL)。
  • 所有大手术均使用外源性FIX,67%输注≤4天;多数小手术、内镜和牙科操作无需或仅需单次FIX输注。
  • 术后出血见于1例小手术和4例牙科操作,无血栓事件或FIX抑制物发生。

核心结论

  • Etranacogene dezaparvovec可能通过减少围手术期外源性FIX需求及其相关风险,促进血友病B患者的围手术期管理。

研究设计与样本

  • 回顾性分析纳入2b期和HOPE-B试验中接受单次2×10¹³ gc/kg etranacogene dezaparvovec输注后分别3年和2年内进行的侵入性操作,共29例参与者64例次操作。

主要发现

  • 64例次操作包括9例大手术、24例小手术、11例内镜、3例内镜伴活检/息肉切除和17例牙科操作。
  • 98%操作前未污染内源性FIX活性达轻型血友病或正常水平,中位43.8 IU/dL(范围3.1-113 IU/dL)。
  • 所有大手术均使用外源性FIX管理,67%输注≤4天。
  • 88%小手术、82%内镜和94%牙科操作无需或仅需单次FIX输注。
  • 术后出血见于1例小手术和4例牙科操作后,无有症状血栓事件或FIX抑制物发生。

临床怎么用

  • 作者认为etranacogene dezaparvovec可能通过减少围手术期外源性FIX需求及其相关风险,促进血友病B患者的围手术期管理。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Little information regarding the management of invasive procedures in people with hemophilia B (HB) after undergoing gene therapy is available. Here, we report the management of invasive procedures in people with severe or moderately severe HB who had previously been treated with etranacogene dezaparvovec in the phase 2b and phase 3 Health Outcomes with Padua Gene; Evaluation in Hemophilia B clinical trials (NCT03489291 and NCT03569891). OBJECTIVES: The objective of this study was to describe the use of exogenous FIX, endogenous FIX activity prior to invasive procedures, and peri- and postoperative bleeds in participants who underwent invasive procedures after receiving etranacogene dezaparvovec gene therapy. METHODS: This retrospective analysis included invasive procedures performed within 3 and 2 years following a single infusion of 2 × 1013 gc/kg of etranacogene dezaparvovec in participants in the phase 2b and Health Outcomes with Padua Gene; Evaluation in Hemophilia B trials, respectively. Data for factor (F)IX dosing, duration of postoperative FIX use, FIX activity prior to invasive procedures, and postoperative bleeds were collected and analyzed. RESULTS: The analysis included 64 procedures in 29 participants: 9 major surgeries, 24 minor surgeries, 11 endoscopies, 3 endoscopies with biopsy/polypectomy, and 17 dental procedures. Uncontaminated endogenous FIX activity corresponded to mild hemophilia or normal levels prior to 98% of all procedures, with a median endogenous FIX activity of 43.8 IU/dL (range, 3.1-113 IU/dL). All major surgeries were managed with exogenous FIX, 67% with ≤4 days of FIX infusion. Most minor surgeries (88%), endoscopies (82%), and dental procedures (94%) were managed with no or a single FIX infusion. Postoperative bleeds occurred after 1 minor surgery and 4 dental procedures. There were no symptomatic thrombotic events or FIX inhibitor developments. CONCLUSION: Etranacogene dezaparvovec has the potential to facilitate perioperative management in people with HB by reducing the need for perioperative exogenous FIX and its associated risks.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. O'Connell N, van der Valk P, Le Quellec S, et al. Invasive procedures and surgery following etranacogene dezaparvovec gene therapy in people with hemophilia B. J Thromb Haemost. 2024. PMID: 39341368. doi:10.1016/j.jtha.2024.08.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。